Pricing Log in Create free account

Nomad Power Solutions, Inc. (NMAD) vs Spero Therapeutics, Inc. (SPRO)

Nomad Power Solutions, Inc. and Spero Therapeutics, Inc. are both Biotechnology companies. Nomad Power Solutions, Inc. and Spero Therapeutics, Inc. are of similar size ($65.9M and $65.8M). Nomad Power Solutions, Inc. has negative trailing earnings, so its P/E is not meaningful; Spero Therapeutics, Inc. trades at 7.9×. Across the 9 metrics below, Spero Therapeutics, Inc. leads on 8 and Nomad Power Solutions, Inc. on 1.

Valuation

Metric NMAD SPRO Biotechnology median
P/E n/m 7.86 8.50
P/S n/m 1.04 9.71
P/B 2.09 1.44 2.13
Price to free cash flow n/m 3.26 20.82
EV/EBITDA n/m 2.16 0.64
EV/Sales n/m 0.21 9.21
Earnings yield (25.77%) 12.73% (33.15%)
Free cash flow yield (10.44%) 30.65% (25.50%)

Profitability

Metric NMAD SPRO Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (68.04%) 19.17% (56.36%)
Return on assets (62.67%) 12.85% (48.04%)
Return on invested capital (40.41%) 0.00% 0.00%

Growth

Metric NMAD SPRO Biotechnology median
Revenue growth (TTM) — 37.24% 6.02%
EPS growth (last fiscal year) 20.75% 111.81% 30.26%
Revenue growth, 5-year CAGR — 48.25% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NMAD SPRO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.87 6.12 4.72
Net debt to EBITDA 1.00 (6.38) 0.96

Dividend

Metric NMAD SPRO Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NMAD SPRO Biotechnology median
Market cap 65.85m 65.80m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack